Nicox S.A

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. Show More...

  • Website https://www.nicox.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.19 EUR
  • Last Updated 29-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share EUR -3.05 -1.15 -0.7 -1.25 -1.43 -1.25 -0.8 -0.13 -0.62 -0.62 -0.62
    Dividends EUR
    Payout Ratio % *
    Shares Mil 14.0 15.0 15.0 15.0 16.0 22.0 24.0 27.0 30.0 30.0 30.0
    Book Value Per Share * EUR 7.21 6.23 5.49 4.17 2.39 5.22 3.15 3.3 4.11 3.44 3.27
    Free Cash Flow Per Share * EUR -3.63 -2.87 -0.95 -1.38 -1.35 -2.26 -1.11 -0.71 -0.41 -0.76
    Return on Assets % -32.51 -15.94 -11.32 -22.99 -15.85 -18.97 -12.2 -2.4 -12.65 -13.45 -13.45
    Financial Leverage (Average) 1.12 1.14 1.13 1.15 1.26 1.61 1.42 1.19 1.22 1.31 1.31
    Return on Equity % -36.12 -18.0 -12.83 -26.18 -19.34 -27.21 -18.49 -3.11 -15.21 -16.97 -16.97
    Return on Invested Capital % -36.31 -18.74 -11.78 -25.23 -17.75 -25.12 -18.42 -3.11 -15.21 -14.78 -14.78
    Interest Coverage -458.13 -5.28 -19.37 -24.15 -25.33 -25.33
    Current Ratio 14.27 13.8 16.27 7.03 4.4 1.4 2.29 5.55 3.23 3.27 3.27
    Quick Ratio 14.1 13.72 16.1 6.8 3.95 1.27 2.25 5.32 3.15 3.02 3.02
    Debt/Equity 0.16 0.010 0.09 0.09